Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2SFd0PV